Pharmacoeconomic analysis of the use of oral iron preparations for the treatment and prevention of iron-deficiency anemia in pregnancy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Iron-deficiency anemia (IDA) in pregnancy is currently an extremely relevant problem. Anemia can complicate the course of pregnancy and delivery, as well as be the cause of fetal malformations. The treatment of IDA in pregnancy is based on the use of iron preparations. The optimal drug choice consists of a set of criteria: the efficiency, tolerance, and cost of the entire cycle of therapy. Objective. To carry out a comparative pharmacoeconomic analysis of Sorbifer Durules and other oral iron preparations for the treatment and prevention of IDA in pregnancy. Material and methods. The pharmacoeconomic analysis method was a cost-effectiveness analysis. To construct models, the investigators used the published results of clinical trials comparing the efficiency of iron treatment in women suffering from IDA during pregnancy. For cost calculations, the average prices of iron preparations as of 26.01.2018 were taken from the website Pharmindex.rf. The average change in hemoglobin levels during treatment was used as a criterion of efficacy Results. The cost-effectiveness values were calculated for iron preparations: Sorbifer Durules (40.43), Tardyferon (32.22), Ferrum Lek(63.72), Maltofer (57.60), Fenules (110.67), TOT’Hma (377.58), Ferro-Folgamma (107.56), Ferlatum (201.63), and Aktiferrin (66.79). Thus, Sorbifer Durules and Tardyferon have the lowest values. Conclusion. The use of Sorbifer Durules and Tardyferon has the most favorable pharmacoeconomic profile for the treatment and prevention of IDA in pregnancy. Sorbifer Durules has an additional advantage since it is available among all oral iron preparations in the largest number of pharmacies.

Full Text

Restricted Access

About the authors

I. V Gribkova

Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Healthcare Department

Email: igribkova@yandex.ru
PhD, Leading Researcher of the Scientific and Clinical Department

M. E Kholovnya-Voloskova

Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Healthcare Department

Email: malwina.holownia@gmail.com
researcher of the Department of Drug Supply and Pharmacoeconomic Analysis

K. I Polyakova

Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Healthcare Department

Email: kseniia.poliakova93@gmail.com
Junior researcher of the Department of Drug Supply and Pharmacoeconomic Analysis

Viktoriya Nikolaevna Stepanova.N

Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Healthcare Department

Email: stepanova.victoria.nikolaevna@gmail.com
Junior researcher of the Scientific and Clinical Department

V. A Dubovtseva

Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Healthcare Department

Email: dubowtsewa.victoria@yandex.ru
researcher of the Department of Drug Supply and Pharmacoeconomic Analysis

A. G Fisun

Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Healthcare Department

Email: PokatiloAnn@gmail.com
Junior researcher of the Scientific and Clinical Department

M. V Davydovskaya

Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University

Email: mdavydovskaya@gmail.com
MD, deputy director for scientific work; Professor of the Department of Neurology, Neurosurgery and Medical Genetics

T. N Ermolaeva

Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Healthcare Department

Email: ermolaeva_mzmo@mail.ru
head of the Department of Drug Supply and Pharmacoeconomic Analysis

References

  1. Тютюнник В.Л., Балушкина А.А., Докуева Р.С.-Э. Профилактика и лечение железодефицитной анемии при беременности. Русский медицинский журнал. 2013; 21(1): 22-5.
  2. Геворкян М.А., Кузнецова Е.М. Анемия беременных: патогенез и принципы терапии. Русский медицинский журнал. 2011; 19(20): 1265-8.
  3. Сельчук В.Ю., Чистяков С.С., Толокнов Б.О., Манзюк Л.В., Никулин М.П., Юрьева Т.В., Кононец П.В., Титова Г.В. Железодефицитная анемия: современное состояние проблемы. РМЖ. Приложение: Онкология. 2012; 3(1): 1-8.
  4. Коноводова Е.Н., Серов В.Н., Бурлев В.А., Тютюнник В.Л., Кан Н.Е., Протопопова Т.А., Сухих Г.Т. Клинический протокол «Диагностика, профилактика и лечение железодефицитных состояний у беременных и родильниц». Акушерство и гинекология. 2012; 4-2(Приложение): 3-9.
  5. Кононова С.В., Кузин В.Б., Ловцова Л.В., Зуева И.А., Ганенков А.А. Фармакологические и клинико-экономические аспекты применения лекарственных препаратов железа (обзор). Медицинский альманах. 2010; 3: 197-201. /Kononova S.V., Kuzin V.B., Lovtsova L.V., Zueva I.A., Ganenkov A.A. Pharmacological and clinical and economic aspects of the use of iron drugs (review). Meditsinskiy almanah. 2010; 3: 197-201. (in Russian)]
  6. Стуклов Н.И., Кунина М.Ю., Семенова Е.Н. Эффективность и переносимость препаратов железа. Что важнее? Существует ли оптимальное решение? Поликлиника. 2014; 2: 48-53.
  7. Сюндюкова Е.Г. Железодефицитная анемия и беременность. Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. 2011; 9(4): 142-7.
  8. Тайпурова А.М. Комплексный анализ эффективности и переносимости современных препаратов железа для лечения анемии беременных. Журнал акушерства и женских болезней. 2005; 54(4): 26-30.
  9. Бапаева М.К. Возможности объективизации выбора ферропрепаратов у беременных, страдающих железодефицитной анемией. Наука, новые технологии и инновации. 2009; 1-2: 34-8.
  10. Таюпова И.М. Сравнительный анализ терапии дефицита железа у беременных. Вестник СурГУ. Медицина. 2013; 3: 39-42.
  11. Семенова Е., Кунина М., Стуклов Н. Роль меди и марганца в метаболизме железа. Врач. 2013; 12: 47-52.
  12. Santiago P. Пероральные препараты двухвалентного и трехвалентного железа для лечения железодефицита. Охрана материнства и детства. 2015; 1: 52-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies